Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Marky1on Feb 11, 2021 8:16pm
307 Views
Post# 32548356

The Way I see it

The Way I see itHas anyone ever seen on Nasdaq a Pharm company spikes up from 5$ to over 100$...up 3,000% in a few days! I can see this happening with our beloved ANTIBE! There are so many positive things in the works. I'm sure that Dr.Haut is already talking to Bayer...They know him very well, thanks to the AskBio deal...and he knows them, who to talk to and how to put an offer on the table. It took him exactly 7 months to complete that deal, 

And don't forget Stern IR! They will play a key role Getting institutions on board , educating them on our great pipeline of drugs

Then we have Dr. Stauffer ( thank you Dan for getting these 2 talented people)...Joe, as I've already said, knows the FDA people in the NSAIDS division, knows what they want and expect from a P3 testing program
According to Christina " ANTIBE will not be completing the P3 testing "....meaning that we will be acquired long before completion 
Bonne Chance to us all...Going to be an amazing year..

<< Previous
Bullboard Posts
Next >>